Cargando…
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy
BACKGROUND: Tamoxifen, a selective oestrogen receptor (ER) modulator, increases bone mineral density (BMD) in postmenopausal women and decreases BMD in premenopausal women. We hypothesised that inherited variants in candidate genes involved in oestrogen signalling and tamoxifen metabolism might be a...
Autores principales: | Henry, N L, Nguyen, A, Azzouz, F, Li, L, Robarge, J, Philips, S, Cao, D, Skaar, T C, Rae, J M, Storniolo, A M, Flockhart, D A, Hayes, D F, Stearns, V |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816645/ https://www.ncbi.nlm.nih.gov/pubmed/19953095 http://dx.doi.org/10.1038/sj.bjc.6605460 |
Ejemplares similares
-
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects
por: Henry, N L, et al.
Publicado: (2013) -
CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005) -
Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes
por: Philips, Santosh, et al.
Publicado: (2012) -
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer
por: Hertz, Daniel L., et al.
Publicado: (2016) -
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.
por: Langdon, S. P., et al.
Publicado: (1990)